Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Average Rating of “Hold” by Analysts

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have earned a consensus rating of “Hold” from the five analysts that are presently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $13.75.

TBPH has been the subject of a number of research reports. StockNews.com lowered Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, August 10th. HC Wainwright dropped their price target on Theravance Biopharma from $20.00 to $15.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Leerink Partners downgraded Theravance Biopharma from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $15.00 to $10.00 in a report on Tuesday, August 6th. TD Cowen dropped their target price on shares of Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating on the stock in a report on Tuesday, August 6th. Finally, Leerink Partnrs downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 6th.

Insider Transactions at Theravance Biopharma

In other Theravance Biopharma news, major shareholder Eli Samaha purchased 999,800 shares of Theravance Biopharma stock in a transaction dated Wednesday, August 7th. The shares were acquired at an average cost of $7.80 per share, with a total value of $7,798,440.00. Following the completion of the transaction, the insider now owns 9,511,150 shares in the company, valued at approximately $74,186,970. The transaction was disclosed in a filing with the SEC, which is available at this link. In other news, SVP Rhonda Farnum sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the transaction, the senior vice president now directly owns 335,965 shares in the company, valued at $3,023,685. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Eli Samaha bought 999,800 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The shares were purchased at an average cost of $7.80 per share, with a total value of $7,798,440.00. Following the acquisition, the insider now directly owns 9,511,150 shares of the company’s stock, valued at $74,186,970. The disclosure for this purchase can be found here. Insiders own 6.90% of the company’s stock.

Institutional Trading of Theravance Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of the business. Oasis Management Co Ltd. increased its stake in shares of Theravance Biopharma by 5.6% during the fourth quarter. Oasis Management Co Ltd. now owns 1,006,858 shares of the biopharmaceutical company’s stock worth $11,317,000 after purchasing an additional 53,604 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its holdings in shares of Theravance Biopharma by 41.6% during the first quarter. Jacobs Levy Equity Management Inc. now owns 557,971 shares of the biopharmaceutical company’s stock valued at $5,005,000 after acquiring an additional 163,951 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Theravance Biopharma by 38.4% in the second quarter. Dimensional Fund Advisors LP now owns 330,181 shares of the biopharmaceutical company’s stock valued at $2,800,000 after acquiring an additional 91,679 shares in the last quarter. Marshall Wace LLP lifted its position in shares of Theravance Biopharma by 83.6% in the second quarter. Marshall Wace LLP now owns 297,499 shares of the biopharmaceutical company’s stock valued at $2,523,000 after acquiring an additional 135,426 shares in the last quarter. Finally, Wellington Management Group LLP boosted its stake in shares of Theravance Biopharma by 68.0% in the fourth quarter. Wellington Management Group LLP now owns 287,102 shares of the biopharmaceutical company’s stock worth $3,227,000 after acquiring an additional 116,164 shares during the last quarter. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Theravance Biopharma Price Performance

Shares of NASDAQ TBPH opened at $8.25 on Friday. The company has a market cap of $403.59 million, a P/E ratio of -9.59 and a beta of 0.24. The firm has a 50-day simple moving average of $8.87 and a two-hundred day simple moving average of $8.95. Theravance Biopharma has a 1 year low of $7.44 and a 1 year high of $11.71.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.25). Theravance Biopharma had a negative net margin of 73.61% and a negative return on equity of 21.29%. The business had revenue of $14.26 million during the quarter, compared to the consensus estimate of $15.81 million. During the same period last year, the company earned ($0.28) EPS. As a group, equities research analysts expect that Theravance Biopharma will post -0.97 EPS for the current year.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.